N. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today recognizes and comments on a paper published online in the February 2009 issue of the Journal of the American College of Cardiology that reinforces the clinical use and impact of its echocardiography contrast agent DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension in hospitalized and critically ill cardiac patients. New data from a prospective, single center, cohort study of over 600 hundred patients find the use of contrast echocardiography with DEFINITY® in technically difficult cases improves endocardial visualization and significantly impacts cardiac diagnosis, resource utilization and patient management decisions. The study authors include Dr. William A. Zoghbi, M.D., F.A.C.C., and his colleagues at Cardiovascular Imaging Institute, The Methodist DeBakey Heart and Vascular Center in Houston, Texas.
